Glycomet SR: Advanced Sustained-Release Metformin for Optimal Glycemic Control
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 180 | $0.24 | $43.17 (0%) | 🛒 Add to cart |
| 270 | $0.21 | $64.76 $57.23 (12%) | 🛒 Add to cart |
| 360 | $0.20
Best per pill | $86.34 $71.28 (17%) | 🛒 Add to cart |
Similar products
Glycomet SR is a scientifically formulated, sustained-release oral antidiabetic medication containing Metformin Hydrochloride. Designed for the management of type 2 diabetes mellitus, it employs a unique extended-release mechanism to ensure a steady and prolonged reduction in blood glucose levels. This formulation minimizes peak-trough fluctuations, enhancing patient tolerability and adherence. It is indicated as monotherapy or in combination with other antidiabetic agents, including insulin, when glycemic targets are not achieved through diet and exercise alone. Its role is pivotal in first-line treatment strategies, aligning with international clinical guidelines for effective and sustained diabetes management.
Features
- Active Ingredient: Metformin Hydrochloride (500 mg or 1000 mg)
- Pharmacological Class: Biguanide antihyperglycemic agent
- Mechanism: Inhibits hepatic gluconeogenesis, increases peripheral glucose uptake and utilization, and delays intestinal glucose absorption
- Formulation: Sustained-release (SR) matrix tablet for once-daily dosing
- Bioavailability: Approximately 50-60%, not affected by food
- Half-life: 6.2 hours; prolonged with sustained-release profile
- Excretion: Primarily renal, unchanged
- Specialized coating: Gastroretentive technology for controlled API release
Benefits
- Provides consistent 24-hour glycemic control with a single daily dose, reducing fasting and postprandial hyperglycemia.
- Lowers HbA1c levels effectively, helping patients achieve and maintain target glycemic goals as per treatment guidelines.
- Associated with a lower incidence of gastrointestinal side effects compared to immediate-release metformin formulations.
- May contribute to modest weight loss or weight neutrality, a significant advantage in overweight or obese diabetic populations.
- Reduces the risk of diabetes-related complications through sustained metabolic control.
- Cost-effective first-line therapy with a well-established efficacy and safety profile.
Common use
Glycomet SR is primarily prescribed for the management of type 2 diabetes mellitus in adults. It is used when glycemic control is not achieved through lifestyle modifications alone. It may be initiated as monotherapy or combined with other oral antidiabetic drugs (e.g., sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors) or insulin. It is also used off-label in certain cases of prediabetes and polycystic ovary syndrome (PCOS) under specialist supervision, owing to its insulin-sensitizing effects.
Dosage and direction
The initial recommended dose is 500 mg once daily, taken with the evening meal. Dosage may be increased gradually in 500 mg increments at weekly intervals, based on glycemic response and tolerability, up to a maximum of 2000 mg once daily. The tablet must be swallowed whole with a glass of water; it should not be crushed, chewed, or split. Administration with food is advised to further minimize potential gastrointestinal discomfort. Regular monitoring of blood glucose and renal function is recommended during therapy.
Precautions
- Renal function must be assessed before initiation and periodically thereafter; use is not recommended if eGFR is below 30 mL/min/1.73m².
- Avoid use in conditions predisposing to renal impairment, such as dehydration, severe infection, or shock.
- Temporary discontinuation is advised prior to iodinated contrast imaging procedures and major surgery.
- Monitor for signs of vitamin B12 deficiency during long-term therapy.
- Use with caution in elderly patients, hepatically impaired individuals, and those consuming alcohol.
- Not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.
Contraindications
- Hypersensitivity to metformin or any excipients in the formulation.
- Severe renal impairment (eGFR <30 mL/min/1.73m²) or renal disease.
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis.
- Acute conditions with risk of renal impairment: dehydration, severe infection, hypoxic states.
- Acute or chronic disease which may cause tissue hypoxia (e.g., cardiac or respiratory failure, recent myocardial infarction).
- Hepatic impairment.
- Excessive alcohol intake, acute or chronic.
Possible side effect
Common side effects are primarily gastrointestinal and often transient, including:
- Nausea, vomiting
- Diarrhea, abdominal discomfort
- Metallic taste Less common but serious adverse effects require immediate medical attention:
- Lactic acidosis (symptoms include malaise, myalgia, respiratory distress, somnolence)
- Hypoglycemia (especially when used with other glucose-lowering agents)
- Skin reactions such as erythema, pruritus, urticaria
- Vitamin B12 deficiency with prolonged use
Drug interaction
- Alcohol: Increases risk of lactic acidosis.
- Cationic drugs (e.g., amiloride, digoxin, morphine, procainamide, quinidine, quinine, ranitidine, triamterene, trimethoprim, vancomycin): May compete for renal tubular secretion and increase metformin levels.
- Iodinated contrast media: Risk of acute renal failure; temporarily discontinue Glycomet SR.
- Hypoglycemic agents (e.g., sulfonylureas, insulin): Additive effect, increasing hypoglycemia risk.
- glucocorticoids, diuretics, sympathomimetics: May reduce hypoglycemic effect.
Missed dose
If a dose is missed, it should be taken as soon as remembered on the same day. If it is nearly time for the next dose, skip the missed dose and resume the regular schedule. Do not take a double dose to make up for the missed one.
Overdose
Overdose may lead to hypoglycemia and lactic acidosis. Symptoms include extreme weakness, nausea, vomiting, abdominal pain, hypothermia, hypotension, and tachycardia. Hypoglycemia may not occur in the absence of other concomitant glucose-lowering agents. In case of suspected overdose, seek immediate medical attention. Management includes supportive measures, blood glucose monitoring, and hemodialysis if necessary (metformin is dialyzable).
Storage
Store below 30°C, in a dry place, protected from light and moisture. Keep in the original blister pack until use. Keep out of reach of children. Do not use after the expiration date printed on the packaging.
Disclaimer
This information is intended for medical professionals and educated patients and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or therapeutic regimen. Do not disregard professional medical advice or delay in seeking it because of something you have read in this product card.
Reviews
“Glycomet SR has significantly improved glycemic stability in my patients with type 2 diabetes, with markedly better GI tolerance compared to the immediate-release formulation. The once-daily dosing enhances compliance.” — Endocrinologist, Mumbai
“As a primary care physician, I find Glycomet SR to be a reliable first-line option. The sustained release provides smooth glucose-lowering effect throughout the day.” — General Practitioner, Chennai
“Patient feedback has been overwhelmingly positive regarding reduced side effects. The convenience of single daily dosing is a major advantage for long-term therapy.” — Diabetologist, New Delhi
“Effective in combination therapy, particularly with DPP-4 inhibitors. A cornerstone in modern diabetes management.” — Consultant Physician, Bangalore